These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 1343089)
1. Three years' continuous low-dose interferon-alpha treatment of hairy-cell leukaemia: evaluation of response and maintenance dose. Nielsen B; Braide I Eur J Haematol; 1992 Oct; 49(4):174-9. PubMed ID: 1343089 [TBL] [Abstract][Full Text] [Related]
2. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. Moormeier JA; Ratain MJ; Westbrook CA; Vardiman JW; Daly KM; Golomb HM J Natl Cancer Inst; 1989 Aug; 81(15):1172-4. PubMed ID: 2746669 [TBL] [Abstract][Full Text] [Related]
3. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL. Federico M; Frassoldati A; Lamparelli T; Foà R; Brugiatelli M; Annino L; Baldini L; Capnist G; Chisesi T; di Celle PF Ann Oncol; 1994 Oct; 5(8):725-31. PubMed ID: 7826905 [TBL] [Abstract][Full Text] [Related]
4. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Smith JW; Longo DL; Urba WJ; Clark JW; Watson T; Beveridge J; Conlon KC; Sznol M; Creekmore SP; Alvord WG Blood; 1991 Oct; 78(7):1664-71. PubMed ID: 1912555 [TBL] [Abstract][Full Text] [Related]
6. Interferon in the treatment of hairy cell leukemia. Thompson JA; Fefer A Cancer; 1987 Feb; 59(3 Suppl):605-9. PubMed ID: 3542183 [TBL] [Abstract][Full Text] [Related]
7. Hairy cell leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. Troussard X; Flandrin G Leuk Lymphoma; 1994; 14 Suppl 1():99-105. PubMed ID: 7820062 [TBL] [Abstract][Full Text] [Related]
8. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b. Glaspy JA; Souza L; Scates S; Narachi M; Blatt L; Ambersley J; Golde DW J Immunother (1991); 1992 Apr; 11(3):198-208. PubMed ID: 1381218 [TBL] [Abstract][Full Text] [Related]
9. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793 [TBL] [Abstract][Full Text] [Related]
10. Very low dose alpha-2b interferon for the treatment of hairy cell leukemia. Thompson JA; Kidd P; Rubin E; Fefer A Blood; 1989 May; 73(6):1440-3. PubMed ID: 2713488 [TBL] [Abstract][Full Text] [Related]
11. Peripheral and intrasplenic platelet kinetics and bone marrow megakaryopoiesis in alpha-2b-interferon treated hairy cell leukemia. Wadenvik H; Braide I; Ridell B; Kutti J; Jacobsson S; Revesz P Leuk Res; 1994 Aug; 18(8):569-75. PubMed ID: 8065159 [TBL] [Abstract][Full Text] [Related]
13. Early response to alpha interferon in a patient affected by hairy cell leukemia. Di Raimondo F; Murolo D; Milone G; Cacciola E; Giustolisi R Haematologica; 1992; 77(4):355-6. PubMed ID: 1427445 [TBL] [Abstract][Full Text] [Related]
14. A randomized comparison of two doses of human lymphoblastoid interferon-alpha in hairy cell leukemia. Wellcome HCL Study Group. Smalley RV; Anderson SA; Tuttle RL; Connors J; Thurmond LM; Huang A; Castle K; Magers C; Whisnant JK Blood; 1991 Dec; 78(12):3133-41. PubMed ID: 1742480 [TBL] [Abstract][Full Text] [Related]
15. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin]. Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434 [TBL] [Abstract][Full Text] [Related]
16. Whole blood assay for NK activity in splenectomized and non-splenectomized hairy cell leukemia patients during IFN-alpha-2b treatment. Nielsen B; Hokland P; Ellegaard J; Hasselbalch H; Hokland M Leuk Res; 1989; 13(6):451-6. PubMed ID: 2770329 [TBL] [Abstract][Full Text] [Related]
17. Human recombinant interferon-alpha-2 in the treatment of patients with hairy cell leukemia. Skotnicki AB; Wolska-Smolen T; Blicharski J; Zduńczyk A; Sasiadek U; Pituch-Noworolska A Cancer Detect Prev; 1988; 12(1-6):511-22. PubMed ID: 3180143 [TBL] [Abstract][Full Text] [Related]
18. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b. Bergsagel DE; Messner H Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493 [TBL] [Abstract][Full Text] [Related]
19. Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia. Ozer H; Golomb HM; Zimmerman H; Spiegel RJ J Natl Cancer Inst; 1989 Apr; 81(8):594-602. PubMed ID: 2495367 [TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment. Lauria F; Rondelli D; Raspadori D; Zinzani PL; Benfenati D; Pileri S; Sabattini E; Tura S Leuk Lymphoma; 1992 May; 7(1-2):103-7. PubMed ID: 1472920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]